<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of chronic hepatitis C virus infection in the patient with HIV</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of chronic hepatitis C virus infection in the patient with HIV</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of chronic hepatitis C virus infection in the patient with HIV</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jürgen Kurt Rockstroh, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David L Thomas, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allyson Bloom, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The consequences of hepatitis C virus (HCV) infection in patients with HIV are significant and include accelerated liver disease progression, high rates of end-stage liver disease, and shortened lifespan after hepatic decompensation, in particular among those with more advanced immunodeficiency [<a href="#rid1">1-3</a>]. In the era of potent antiretroviral therapy (ART), end-stage liver disease remains a major cause of death among patients with HIV who have HCV coinfection [<a href="#rid4">4,5</a>]. </p><p>This topic will address the management of patients with HIV/HCV coinfection.</p><p>Discussion of recently acquired HCV infection is found elsewhere. (See  <a class="medical medical_review" href="/d/html/3650.html" rel="external">"Clinical manifestations, diagnosis, and treatment of acute hepatitis C virus infection in adults"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">GOALS OF THERAPY</span><span class="headingEndMark"> — </span>The objective of HCV antiviral treatment is to cure HCV infection, as reflected by a sustained virologic response, which is associated with substantial reductions in liver-related morbidity and mortality.</p><p class="headingAnchor" id="H870366386"><span class="h2">Sustained virologic response as cure</span><span class="headingEndMark"> — </span>Successful antiviral therapy is characterized by achievement of a sustained virologic response (SVR), defined as an undetectable HCV RNA 12 to 24 weeks after the end of treatment (ie, SVR12 or SVR24). Since very few patients have rebound viremia between weeks 12 and 24 (or later), SVR12 is increasingly used as a primary endpoint in clinical trials, and in the United States is the recognized endpoint for outcome assessment of the Food and Drug Administration (FDA) [<a href="#rid6">6</a>]. The SVR12 benchmark represents treatment-induced viral eradication, and thus an effective cure [<a href="#rid7">7,8</a>]. </p><p class="headingAnchor" id="H870366392"><span class="h2">Clinical benefits of cure</span><span class="headingEndMark"> — </span>As in the population with HCV monoinfection, HCV eradication in patients with coinfection has been associated with the following clinical benefits [<a href="#rid9">9-11</a>] (see  <a class="medical medical_review" href="/d/html/15832.html" rel="external">"Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection", section on 'Benefits of treatment'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Improvement and/or delayed progression of fibrosis and necroinflammation</p><p class="bulletIndent1"><span class="glyph">●</span>Reduction of morbidity and mortality secondary to liver disease </p><p class="bulletIndent1"><span class="glyph">●</span>Reduced incidence of hepatocellular carcinoma</p><p></p><p>As an example, one observational study of 711 patients with HIV who had been treated for HCV infection demonstrated that an SVR was associated with a reduced risk of liver-related death (3.7 percent versus 0.5 percent) and liver decompensation (9.1 percent versus 0.5 percent) [<a href="#rid12">12</a>]. In another cohort study of 495 patients with HIV and HCV coinfection and compensated cirrhosis, SVR with all-oral direct-acting antiviral (DAA) was associated with a lower risk of hepatocellular carcinoma (0.35 versus 1.79 cases per 100 person-years) [<a href="#rid13">13</a>].</p><p>Another potential benefit of sustained HCV clearance for patients with coinfection may be a reduced risk of drug-induced liver injury associated with antiretroviral therapy (ART) [<a href="#rid14">14</a>]. </p><p>Patients who do not achieve an SVR remain at risk for further liver disease progression. </p><p class="headingAnchor" id="H272125634"><span class="h1">EFFECT OF HIV INFECTION ON RESPONSE TO HCV TREATMENT</span><span class="headingEndMark"> — </span>Although patients with HIV/HCV coinfection traditionally have lower response rates to HCV treatment with peginterferon and <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a> compared with individuals without HIV, they appear to have comparable sustained virologic response (SVR) rates with direct-acting antiviral-based regimens. Thus, results from trials of direct-acting antiviral regimens performed in patients with HCV monoinfection can be extrapolated to inform expected efficacy of such regimens among patients with HIV/HCV coinfection. (See <a class="local">'HCV regimen selection'</a> below.)</p><p>Nevertheless, the potential for drug interactions between antiretroviral and HCV direct-acting antiviral agents remains an important management issue unique to patients with HIV/HCV coinfection. (See <a class="local">'Potential drug interactions with ART'</a> below.)</p><p class="headingAnchor" id="H870365996"><span class="h1">PATIENT EVALUATION</span></p><p class="headingAnchor" id="H870366063"><span class="h2">Evaluation to guide management decisions</span><span class="headingEndMark"> — </span>All patients are better off cured than with chronic HCV infection. Selection of the optimal regimen is based upon several factors, including the infecting genotype in some cases, the stage of the disease, other medical and social priorities, prior treatment history, and drug interactions. Evaluation prior to treatment should focus on these factors and is discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/d/html/15832.html" rel="external">"Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection"</a>.)</p><p class="headingAnchor" id="H272126288"><span class="h2">Deciding when to treat</span><span class="headingEndMark"> — </span>A cure of HCV results in improved survival, reduced morbidity, and higher quality of life in the vast majority of patients (see <a class="local">'Goals of therapy'</a> above). With the growing availability of highly effective interferon-free regimens for HCV, a curative all-oral treatment is a possibility for the vast-majority of patients, including those with HIV coinfection. The very low incidence of adverse events and high efficacy means that almost every patient can benefit from HCV treatment. However, the cost of these new agents complicates universal delivery of antiviral therapy. Because of the more rapid progression to advanced liver disease in the setting of HIV infection, coinfection is one reason to prioritize a patient for HCV antiviral therapy [<a href="#rid15">15-17</a>]. Another reason is cirrhosis or bridging fibrosis. These issues are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/15832.html" rel="external">"Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection", section on 'Deciding when to treat'</a>.)</p><p>Timing of HCV antiviral therapy in relation to ART initiation in ART-naïve patients is discussed in detail below. (See <a class="local">'Timing of ART initiation'</a> below.)</p><p>Treatment of certain patient populations, such as those with decompensated liver disease, remains associated with increased risk of adverse events and should be undertaken only at centers which have expertise in managing HIV/HCV coinfection. </p><p class="headingAnchor" id="H870366027"><span class="h1">ANTIRETROVIRAL MANAGEMENT</span><span class="headingEndMark"> — </span>Antiretroviral management issues in patients with HIV/HCV coinfection for whom HCV treatment is being considered include use of appropriate antiretroviral regimens that do not have serious drug interactions with HCV antiviral agents and the timing of antiretroviral therapy (ART) initiation or switch. Antiretroviral treatment interruption to allow for HCV antiviral therapy is <strong>not</strong> recommended [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H870366158"><span class="h2">ART-naïve patients</span><span class="headingEndMark"> — </span>ART-naïve patients with HIV/HCV coinfection should be initiated on ART for their HIV disease, regardless of their CD4 cell count [<a href="#rid19">19</a>]. In most instances, it is preferable to start ART first and begin HCV therapy later. (See <a class="local">'Timing of ART initiation'</a> below.)</p><p class="headingAnchor" id="H870366275"><span class="h3">Selection of ART regimen</span><span class="headingEndMark"> — </span>When selecting an ART regimen, potential drug-drug interactions with HCV antiviral medications should be taken into account in addition to the other considerations that inform ART choice. (See <a class="local">'Potential drug interactions with ART'</a> below and  <a class="medical medical_review" href="/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"</a>.)</p><p class="headingAnchor" id="H870366290"><span class="h3">Timing of ART initiation</span><span class="headingEndMark"> — </span>We generally initiate ART approximately four to six weeks before starting HCV antiviral therapy. There are two main reasons for this:</p><p class="bulletIndent1"><span class="glyph">●</span>Initiation of ART prior to HCV antiviral therapy allows assessment of tolerability and adverse effects of ART alone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment with ART may theoretically translate into better HCV outcomes, either through restoration of immune function or other effects of suppressing HIV viremia [<a href="#rid20">20</a>]. </p><p></p><p>Given the breadth of the antiretroviral armamentarium, there are many good choices that can be safely used with HCV direct-acting antiviral (DAA) regimens and thus HIV therapy can generally be started first. </p><p class="headingAnchor" id="H870366303"><span class="h2">ART-experienced patients</span><span class="headingEndMark"> — </span>Patients with HIV/HCV coinfection who have achieved HIV viral suppression on an ART regimen that they tolerate can continue the regimen if it does not have any expected significant drug interactions with the selected HCV treatment regimen. In contrast, a regimen switch may be indicated if components of the ART regimen cannot be used with the HCV antiviral agents. Additionally, if an ART regimen switch is indicated because of failure to suppress HIV or intolerance, potential drug interactions with HCV antivirals should be taken into account in addition to the other considerations that inform ART choice in treatment-experienced patients. (See <a class="local">'Potential drug interactions with ART'</a> below and  <a class="medical medical_review" href="/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV"</a> and  <a class="medical medical_review" href="/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy"</a>.) </p><p>In cases of ART regimen switches, the prior antiretroviral history and resistance profiles should be carefully studied to ensure that the new regimen includes two to three fully active antiretroviral agents. In general, HCV therapy is started four to six weeks after an ART regimen switch to allow for assessment of tolerability and adverse events of the new ART regimen alone. Additionally, HIV RNA is measured within four to eight weeks after the ART regimen switch to ensure that the new regimen maintains viral suppression. If the new ART regimen is to be switched back to the original ART regimen following HCV treatment, this should be delayed until at least two weeks after the completion of the HCV treatment to ensure clearance of the HCV antivirals [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H345778634"><span class="h1">HCV REGIMEN SELECTION</span></p><p class="headingAnchor" id="H1469007307"><span class="h2">Regimen options</span><span class="headingEndMark"> — </span>The regimen options for patients with HIV/HCV coinfection are the same as those for patients with HCV monoinfection. Where available, pangenotypic regimens (eg, <a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> and <a class="drug drug_general" data-topicid="114296" href="/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a> for initial antiviral therapy) are generally preferred options  (<a class="graphic graphic_algorithm graphicRef93587" href="/d/graphic/93587.html" rel="external">algorithm 1</a>); they can facilitate therapy because they can be used without prior genotype assessment [<a href="#rid15">15,18</a>]. When several regimens are available for a given genotype, potential drug interactions with the antiretroviral regimen are a critical factor in deciding between them for patients with coinfection. (See <a class="local">'Potential drug interactions with ART'</a> below.)</p><p>Selection and administration of antiviral regimens for chronic HCV infection are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/16592.html" rel="external">"Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults"</a> and  <a class="medical medical_review" href="/d/html/15795.html" rel="external">"Management of chronic hepatitis C virus infection: Antiviral retreatment following relapse in adults"</a>.)</p><p>Several studies have demonstrated that patients with coinfection achieve high sustained virologic response (SVR) rates with direct-acting antiviral (DAA) regimens that are comparable to those seen in patients with monoinfection [<a href="#rid21">21,22</a>]. Examples include: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glecaprevir-pibrentasvir</strong> – <a class="drug drug_general" data-topicid="114296" href="/d/drug information/114296.html" rel="external">Glecaprevir-pibrentasvir</a> is a potent, highly effective pangenotypic regimen. In a study of patients with HIV/HCV coinfection treated with glecaprevir-pibrentasvir, an eight-week course resulted in SVR in all of the patients with genotype 1 (n = 87), genotype 2 (n = 9), and genotype 3 (n = 22) infection and no cirrhosis [<a href="#rid23">23</a>]. Patients with cirrhosis received a 12-week course in that study; none of the 10 patients with genotype 1 and only one of the four patients with genotype 3 infection experienced virologic failure. (See  <a class="medical medical_review" href="/d/html/16592.html" rel="external">"Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults", section on 'Glecaprevir-pibrentasvir'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sofosbuvir-velpatasvir</strong> – <a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">Sofosbuvir-velpatasvir</a> is a potent, highly effective pangenotypic regimen. In a study of patients with HIV/HCV coinfection treated with sofosbuvir-velpatasvir for 12 weeks, SVR rates were 95 percent for genotype 1 (n = 78), 100 percent for genotype 2 (n = 11), and 92 percent for genotype 3 (n = 92 percent) [<a href="#rid24">24</a>]. Some patients failed to achieve SVR because of loss to follow-up (rather than known virologic failure); SVR rates were high regardless of the presence of cirrhosis or treatment history. (See  <a class="medical medical_review" href="/d/html/16592.html" rel="external">"Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults", section on 'Sofosbuvir-velpatasvir'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sofosbuvir-velpatasvir-voxilaprevir</strong> – This regimen is generally reserved for patients who have previously failed contemporary DAA-based regimens (although in Europe there is an approved eight-week option for initial treatment). Its efficacy has not been directly studied in populations with HIV/HCV coinfection but is thought to be comparable to that in patients with HCV monoinfection. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Daclatasvir</strong><strong> plus </strong><strong>sofosbuvir</strong> – This combination is used in locations where pangenotypic regimens are not accessible, and it is highly effective in coinfection with genotypes 1, 2, 3, and 4 [<a href="#rid25">25-31</a>]. In a study of over 200 patients with coinfection, 83 percent of whom had genotype 1 infection, 12 weeks of daclatasvir plus <a class="drug drug_general" data-topicid="91794" href="/d/drug information/91794.html" rel="external">sofosbuvir</a> resulted in SVR rates of 97 and 98 percent among treatment-naïve and treatment-experienced patients, respectively [<a href="#rid25">25</a>]. All of 10 patients with genotype 3 infection achieved SVR. SVR rates were lower (76 percent) when given for only eight weeks. Allowed antiretroviral agents included <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a>, <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a>, or lopinavir (each ritonavir-boosted), <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a>, <a class="drug drug_general" data-topicid="9694" href="/d/drug information/9694.html" rel="external">nevirapine</a>, <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a>, <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a>, and <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a>. Daclatasvir dose was adjusted when used with certain antiretrovirals (30 mg with protease inhibitors and 90 mg with efavirenz and nevirapine). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ledipasvir-sofosbuvir</strong> – This is an option for patients with genotypes 1, 4, 5, and 6 infection. It is highly effective in patients with coinfection [<a href="#rid32">32,33</a>]. As an example, in the ION-4 study, which included over 300 treatment-naïve and treatment-experienced patients with genotype 1 coinfection, <a class="drug drug_general" data-topicid="97562" href="/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a> for 12 weeks resulted in a high sustained virologic response (SVR) rate overall (96 percent) and even among patients with cirrhosis (94 percent) or prior treatment failure (97 percent) [<a href="#rid33">33</a>]. Analysis of data from patients with monoinfection has suggested that ledipasvir-sofosbuvir for 8 weeks is equally effective as 12 weeks for HCV treatment-naïve patients without cirrhosis who also have an HCV viral load &lt;6 million international units/mL. Although this abbreviated course in the setting of coinfection is not routinely recommended [<a href="#rid18">18</a>], observational data evaluating use of this eight-week course in patients with coinfection are reassuring [<a href="#rid34">34</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elbasvir-grazoprevir</strong> – This is a potential option for patients with genotype 1 and 4 infection and is highly effective in patients with coinfection [<a href="#rid35">35-37</a>]. In a study of 189 treatment-naïve patients with HIV/HCV genotype 1 coinfection, SVR with 12 weeks of <a class="drug drug_general" data-topicid="106574" href="/d/drug information/106574.html" rel="external">elbasvir-grazoprevir</a> was 94 percent [<a href="#rid36">36</a>]. SVR rates were comparably high among the 16 percent who had cirrhosis. Analysis of outcomes among patients with monoinfection has suggested an association between lower SVR rates and pre-existing variations in the NS5A inhibitor sequence of genotype 1a virus. Therefore, American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) guidelines recommend that if elbasvir-grazoprevir is considered for patients with genotype 1a, they undergo testing for resistance-associated substitutions (RASs) and, if RASs are present, receive a different regimen [<a href="#rid18">18</a>]; European Association for the Study of the Liver (EASL) guidelines recommend elbasvir-grazoprevir for genotype 1b patients only [<a href="#rid15">15</a>]. </p><p></p><p>Other direct-acting antivirals are available in certain other locations. Clinicians in those locations are advised to check local guidelines on the optimal use of such agents.</p><p class="headingAnchor" id="H870364631"><span class="h2">Potential drug interactions with ART</span><span class="headingEndMark"> — </span>Several important drug interactions between antiretroviral therapy (ART) and HCV antiviral agents should be considered when assessing a patient with HIV/HCV coinfection for HCV treatment  (<a class="graphic graphic_table graphicRef109363" href="/d/graphic/109363.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H2802794223"><span class="h3">Sofosbuvir-velpatasvir</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">Sofosbuvir-velpatasvir</a> is available in a fixed-dose combination  (<a class="graphic graphic_table graphicRef109363" href="/d/graphic/109363.html" rel="external">table 1</a>). In relatively small clinical studies of patients with HIV/HCV coinfection who were treated with sofosbuvir-velpatasvir, antiretroviral agents that were concurrently used without evidence of decreased efficacy or adverse effect included <a class="drug drug_general" data-topicid="8993" href="/d/drug information/8993.html" rel="external">abacavir</a>, <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a>, <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a>, <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a>, <a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">elvitegravir</a>, <a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">emtricitabine</a>, <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a>, <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a>, <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a>, <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a>, and TDF [<a href="#rid24">24</a>]. Pharmacokinetic studies in healthy volunteers have also not shown clinically relevant drug level changes when sofosbuvir-velpatasvir is used with any of these, <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a>, bictegravir, or <a class="drug drug_general" data-topicid="110861" href="/d/drug information/110861.html" rel="external">tenofovir alafenamide</a> [<a href="#rid38">38-40</a>]. No clinically relevant drug interactions with <a class="drug drug_general" data-topicid="130319" href="/d/drug information/130319.html" rel="external">cabotegravir</a> or <a class="drug drug_general" data-topicid="118920" href="/d/drug information/118920.html" rel="external">doravirine</a> are expected. </p><p>Coadministration of <a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> with some antiretroviral regimens containing TDF results in elevated levels of tenofovir in pharmacokinetic studies, although the clinical significance of these levels is uncertain. If these agents are used together, monitoring for renal toxicity is warranted, as for coadministration with <a class="drug drug_general" data-topicid="97562" href="/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a> (see <a class="local">'Ledipasvir-sofosbuvir'</a> below). These changes in tenofovir levels are not seen with tenofovir-alafenamide-containing regimens. </p><p>Both <a class="drug drug_general" data-topicid="91794" href="/d/drug information/91794.html" rel="external">sofosbuvir</a> and velpatasvir are substrates of P-glycoprotein transporter. Thus, concomitant use of <a class="drug drug_general" data-topicid="9459" href="/d/drug information/9459.html" rel="external">tipranavir</a>, which is a P-gp inducer, is <strong>not</strong> recommended because it is expected to decrease velpatasvir and sofosbuvir levels. However, a small pharmacokinetic study suggests that P-gp inhibition by <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a>, with which tipranavir is always coadministered, may negate this effect [<a href="#rid41">41</a>].</p><p>Velpatasvir is CYP2B6 substrate. Coadministration with <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a>, a CYP2B6 inducer, is also <strong>not</strong> recommended because of significant decreases in velpatasvir levels.</p><p>Other important drug interactions with <a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> are discussed elsewhere and can be queried in the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate. (See  <a class="medical medical_review" href="/d/html/93242.html" rel="external">"Direct-acting antivirals for the treatment of hepatitis C virus infection", section on 'Sofosbuvir-velpatasvir'</a>.)</p><p class="headingAnchor" id="H1895314580"><span class="h3">Glecaprevir-pibrentasvir</span><span class="headingEndMark"> — </span>Glecaprevir and pibrentasvir are available only as a fixed-dose combination. They are substrates and inhibitors of P-glycoprotein, breast cancer resistance protein (BCRP), and organic anion transporting polypeptide (OATP) 1B1/3. Thus, coadministration with several antiretrovirals is not advised  (<a class="graphic graphic_table graphicRef109363" href="/d/graphic/109363.html" rel="external">table 1</a>). </p><p>Use with <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> is not recommended because of the potential for decreased levels of glecaprevir and pibrentasvir. </p><p>Use with <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a> is contraindicated because of the risk of aminotransferase elevations. Use with other protease inhibitors (including <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a>, lopinavir, and <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a>) is not recommended because of the potential for increased levels of glecaprevir and pibrentasvir. </p><p>In clinical studies of patients with HIV/HCV coinfection who were treated with <a class="drug drug_general" data-topicid="114296" href="/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a>, antiretroviral agents that were concurrently used without evidence of decreased efficacy or adverse effect included tenofovir (both TDF and TAF), <a class="drug drug_general" data-topicid="8993" href="/d/drug information/8993.html" rel="external">abacavir</a>, <a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">emtricitabine</a>, <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a>, <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a>, <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a>, <a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">elvitegravir</a> with <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a>, and <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a> [<a href="#rid23">23</a>]. No clinically relevant drug interactions with bictegravir, <a class="drug drug_general" data-topicid="130319" href="/d/drug information/130319.html" rel="external">cabotegravir</a>, or <a class="drug drug_general" data-topicid="118920" href="/d/drug information/118920.html" rel="external">doravirine</a> are expected. However, the European product label for <a class="drug drug_general" data-topicid="116731" href="/d/drug information/116731.html" rel="external">bictegravir-emtricitabine-tenofovir alafenamide</a> notes caution when used with glecaprevir-pibrentasvir because levels of bictegravir, a P-glycoprotein and BCRP substrate, may be elevated with coadministration [<a href="#rid42">42</a>]. </p><p>Other important drug interactions with <a class="drug drug_general" data-topicid="114296" href="/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a> are discussed elsewhere and can be queried in the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate. (See  <a class="medical medical_review" href="/d/html/93242.html" rel="external">"Direct-acting antivirals for the treatment of hepatitis C virus infection"</a>.)</p><p class="headingAnchor" id="H2419824943"><span class="h3">Voxilaprevir</span><span class="headingEndMark"> — </span>Voxilaprevir is only available as a combination pill with <a class="drug drug_general" data-topicid="91794" href="/d/drug information/91794.html" rel="external">sofosbuvir</a> and velpatasvir. Its use is generally reserved for patients who have failed prior treatment with certain DAA-containing regimens. Voxilaprevir is a substrate and inhibitor of P-glycoprotein, BCRP, and OATP 1B1 and 1B3. It is also slowly metabolized by CYP34A. Thus, coadministration with several antiretrovirals is not advised  (<a class="graphic graphic_table graphicRef109363" href="/d/graphic/109363.html" rel="external">table 1</a>). </p><p>Use with <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> is not recommended because of potentially decreased levels of voxilaprevir.</p><p>Use with <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a> or lopinavir is not recommended because of potentially increased levels of voxilaprevir. For similar reasons, use of other DAA regimens is recommended for patients on <a class="drug drug_general" data-topicid="128916" href="/d/drug information/128916.html" rel="external">fostemsavir</a>.</p><p>In pharmacokinetic studies of <a class="drug drug_general" data-topicid="114088" href="/d/drug information/114088.html" rel="external">sofosbuvir-velpatasvir-voxilaprevir</a>, there were no concerning drug levels when given with tenofovir (both TDF and TAF), <a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">emtricitabine</a>, <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a>, <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a>, bictegravir, and <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a> [<a href="#rid39">39,40</a>]. No clinically relevant drug interactions with <a class="drug drug_general" data-topicid="118920" href="/d/drug information/118920.html" rel="external">doravirine</a> or <a class="drug drug_general" data-topicid="130319" href="/d/drug information/130319.html" rel="external">cabotegravir</a> are expected. Voxilaprevir levels were higher when coadministered with boosted regimens (ie, <a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">elvitegravir</a> with <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a> and <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a> with <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a> or cobicistat), but these levels were not thought to be clinically relevant. </p><p>Coadministration of <a class="drug drug_general" data-topicid="114088" href="/d/drug information/114088.html" rel="external">sofosbuvir-velpatasvir-voxilaprevir</a> with some antiretroviral regimens containing TDF is expected to result in elevated levels of tenofovir (as with <a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a>), although the clinical significance of these levels is uncertain. If these agents are used together, monitoring for renal toxicity is warranted, as for coadministration with <a class="drug drug_general" data-topicid="97562" href="/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a> (see <a class="local">'Ledipasvir-sofosbuvir'</a> below). </p><p class="headingAnchor" id="H776985236"><span class="h3">Ledipasvir-sofosbuvir</span><span class="headingEndMark"> — </span>Ledipasvir is only available as a fixed-dose combination with <a class="drug drug_general" data-topicid="91794" href="/d/drug information/91794.html" rel="external">sofosbuvir</a>  (<a class="graphic graphic_table graphicRef109363" href="/d/graphic/109363.html" rel="external">table 1</a>). Coadministration of <a class="drug drug_general" data-topicid="97562" href="/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a> with <a class="drug drug_general" data-topicid="9895" href="/d/drug information/9895.html" rel="external">tenofovir disoproxil fumarate</a> (TDF) results in elevated levels of tenofovir in pharmacokinetic studies, and levels are even higher when measured intracellularly or in the setting of concurrent use with certain other antiretrovirals [<a href="#rid43">43-45</a>]. The clinical significance of such levels of tenofovir is uncertain. Nevertheless, given the paucity of safety data in individuals with HIV and the lack of clear correlation between drug levels and toxicity, conservative management is warranted until there is greater experience. </p><p class="bulletIndent1"><span class="glyph">●</span>Because coadministration with <a class="drug drug_general" data-topicid="110861" href="/d/drug information/110861.html" rel="external">tenofovir alafenamide</a> (TAF) does not result in elevated plasma levels of tenofovir and TAF is associated with less renal and bone toxicity than TDF [<a href="#rid46">46,47</a>], we switch patients from a TDF- to a TAF-containing regimen when planning to use <a class="drug drug_general" data-topicid="97562" href="/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When TAF is not an option, management depends on the precise TDF-containing antiretroviral regimen and the renal function of the patient; consultation with an HIV pharmacologist can be useful in this setting. Some TDF-based regimens can be used with <a class="drug drug_general" data-topicid="97562" href="/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a>. If that is undertaken, we check a baseline creatinine, urinalysis, and phosphate level and monitor for tenofovir-associated renal toxicity (eg, with creatinine and phosphate at least monthly). If there is evidence of significant renal toxicity, consultation with a renal expert is warranted. Specific options for different TDF-containing antiretroviral regimens are as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Concomitant use of <a class="drug drug_general" data-topicid="97562" href="/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a> with the combination regimen of <a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">elvitegravir</a>, <a class="drug drug_general" data-topicid="97309" href="/d/drug information/97309.html" rel="external">cobicistat</a>, TDF, and <a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">emtricitabine</a> (ECF-TDF) is <strong>not</strong> recommended because of the uncertainty of the safety of tenofovir levels reported in this setting [<a href="#rid43">43</a>]. Combination of elvitegravir, cobicistat, TAF, and emtricitabine (ECF-TAF), however, is possible. If this formulation is not available, a different antiretroviral regimen or a different HCV regimen should be chosen. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who are on TDF plus a ritonavir-boosted protease inhibitor (eg, <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a>, <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a>), we use <a class="drug drug_general" data-topicid="97562" href="/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a> cautiously and with increased renal monitoring if their baseline renal function is normal. However, for patients with some renal impairment at baseline (that does not preclude ledipasvir-sofosbuvir use), we are more likely to change either the backbone to <a class="drug drug_general" data-topicid="9010" href="/d/drug information/9010.html" rel="external">abacavir-lamivudine</a>, or the third drug to <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a>, <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a>, or <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a> prior to using ledipasvir-sofosbuvir, provided that the new antiretroviral regimen is expected to be effective based on baseline genotype and prior treatment history.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The expected increase in tenofovir levels when TDF and <a class="drug drug_general" data-topicid="97562" href="/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a> are coadministered is lower for nonnucleoside reverse transcriptase inhibitor- or integrase inhibitor-containing regimens, and in such cases, we use ledipasvir-sofosbuvir cautiously and with increased renal monitoring. In clinical studies of patients with HIV/HCV coinfection who were treated with ledipasvir-sofosbuvir, antiretroviral agents that were concurrently used without evidence of decreased efficacy or adverse effect included TDF plus <a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">emtricitabine</a> with <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a>, <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a>, or <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a> [<a href="#rid32">32,33</a>]. In one study of over 300 patients who received ledipasvir-sofosbuvir plus one of those antiretroviral regimens, only four patients had an increase in the serum creatinine level ≥0.4 mg/dL; two remained on TDF, one had the TDF dose reduced, and one discontinued TDF [<a href="#rid33">33</a>].</p><p></p><p>Clinically significant interactions are not expected or have not been observed in healthy individuals with <a class="drug drug_general" data-topicid="8993" href="/d/drug information/8993.html" rel="external">abacavir</a>, ritonavir-boosted <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a>, ritonavir-boosted <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a>, bictegravir, <a class="drug drug_general" data-topicid="118920" href="/d/drug information/118920.html" rel="external">doravirine</a> [<a href="#rid48">48</a>], and <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a>. Although <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a> and <a class="drug drug_general" data-topicid="130319" href="/d/drug information/130319.html" rel="external">cabotegravir</a> may not have been explicitly studied with <a class="drug drug_general" data-topicid="97562" href="/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a>, based on metabolism pathways, it is appropriate to extrapolate that they can be safely used concomitantly.</p><p>Other important drug interactions with <a class="drug drug_general" data-topicid="97562" href="/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a> are discussed elsewhere and can be queried in the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate. (See  <a class="medical medical_review" href="/d/html/93242.html" rel="external">"Direct-acting antivirals for the treatment of hepatitis C virus infection", section on 'Ledipasvir-sofosbuvir'</a>.)</p><p class="headingAnchor" id="H2847656837"><span class="h3">Elbasvir-grazoprevir</span><span class="headingEndMark"> — </span>Elbasvir and grazoprevir are available only as a fixed-dose combination. Both are primarily metabolized through CYP3A metabolism, and grazoprevir is a substrate of OATP1B1/3 as well. Thus, coadministration with several antiretrovirals is not advised  (<a class="graphic graphic_table graphicRef109363" href="/d/graphic/109363.html" rel="external">table 1</a>). </p><p>Use with <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> is contraindicated because of the potential for decreased levels of elbasvir and grazoprevir. Use with <a class="drug drug_general" data-topicid="8902" href="/d/drug information/8902.html" rel="external">etravirine</a> is not recommended for similar reasons. </p><p>Use with protease inhibitors (including <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a> and <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a>) is contraindicated because of the risk of elevated levels of grazoprevir. Use with cobicistat-containing regimens and <a class="drug drug_general" data-topicid="128916" href="/d/drug information/128916.html" rel="external">fostemsavir</a> is not recommended for similar reasons. </p><p>In clinical studies of patients with HIV/HCV coinfection who were treated with <a class="drug drug_general" data-topicid="106574" href="/d/drug information/106574.html" rel="external">elbasvir-grazoprevir</a>, antiretroviral agents that were concurrently used without evidence of decreased efficacy or adverse effect included tenofovir, <a class="drug drug_general" data-topicid="8993" href="/d/drug information/8993.html" rel="external">abacavir</a>, <a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">emtricitabine</a>, <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a>, <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a>, <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a>, and <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a> [<a href="#rid36">36</a>]. No clinically relevant drug interactions with <a class="drug drug_general" data-topicid="118920" href="/d/drug information/118920.html" rel="external">doravirine</a> have been observed in pharmacokinetic studies [<a href="#rid48">48</a>], and none are expected with bictegravir or <a class="drug drug_general" data-topicid="130319" href="/d/drug information/130319.html" rel="external">cabotegravir</a>. </p><p>Other important drug interactions with <a class="drug drug_general" data-topicid="106574" href="/d/drug information/106574.html" rel="external">elbasvir-grazoprevir</a> are discussed elsewhere and can be queried in the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate. (See  <a class="medical medical_review" href="/d/html/93242.html" rel="external">"Direct-acting antivirals for the treatment of hepatitis C virus infection", section on 'Elbasvir-grazoprevir'</a>.)</p><p class="headingAnchor" id="H3960967758"><span class="h3">Sofosbuvir</span><span class="headingEndMark"> — </span>Overall, <a class="drug drug_general" data-topicid="91794" href="/d/drug information/91794.html" rel="external">sofosbuvir</a> has few drug interactions with antiretroviral agents  (<a class="graphic graphic_table graphicRef109363" href="/d/graphic/109363.html" rel="external">table 1</a>), as it is not metabolized by and has no effect on the hepatic P450 enzyme complex, of which many antiretroviral agents are inducers or inhibitors. The main exception is <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a> boosted <a class="drug drug_general" data-topicid="9459" href="/d/drug information/9459.html" rel="external">tipranavir</a>, which is <strong>not</strong> recommended for use with sofosbuvir because it is expected to decrease sofosbuvir levels since tipranavir is an inducer of the P-glycoprotein transporter. (See <a class="local">'Sofosbuvir-velpatasvir'</a> above.)</p><p>In clinical studies of patients with HIV/HCV coinfection who were treated with <a class="drug drug_general" data-topicid="91794" href="/d/drug information/91794.html" rel="external">sofosbuvir</a>, antiretroviral agents that were concurrently used without any evidence of decreased efficacy or adverse effect included <a class="drug drug_general" data-topicid="8527" href="/d/drug information/8527.html" rel="external">tenofovir disoproxil fumarate-emtricitabine</a> (TDF-FTC), <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a>, <a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a> boosted <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a>, ritonavir boosted <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a>, <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a>, and <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a> [<a href="#rid49">49</a>]. Although other commonly used antiretroviral agents, such as <a class="drug drug_general" data-topicid="8993" href="/d/drug information/8993.html" rel="external">abacavir</a>, <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a>, bictegravir, <a class="drug drug_general" data-topicid="130319" href="/d/drug information/130319.html" rel="external">cabotegravir</a>, and <a class="drug drug_general" data-topicid="97308" href="/d/drug information/97308.html" rel="external">elvitegravir</a>, may not have been explicitly studied with sofosbuvir, based on the metabolism pathway, it is appropriate to extrapolate that these agents can be safely used with sofosbuvir. </p><p>There are potential interactions between <a class="drug drug_general" data-topicid="91794" href="/d/drug information/91794.html" rel="external">sofosbuvir</a> and other agents from different drug classes, and thus consideration of drug interactions is essential. As an example, sofosbuvir-containing regimens should not be used with <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> because of reported cases of severe bradycardia with concomitant use. Other important drug interactions with sofosbuvir are discussed elsewhere and can be queried in the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate. (See  <a class="medical medical_review" href="/d/html/93242.html" rel="external">"Direct-acting antivirals for the treatment of hepatitis C virus infection", section on 'Sofosbuvir'</a>.)</p><p class="headingAnchor" id="H3441171844"><span class="h3">Less commonly used agents</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Daclatasvir</strong> — Daclatasvir may be used in combination with <a class="drug drug_general" data-topicid="91794" href="/d/drug information/91794.html" rel="external">sofosbuvir</a> to treat HCV infection. It is metabolized by the CYP3A subfamily, which consists mainly of hepatic and intestinal CYP3A4 metabolism, thus significant inducers or inhibitors of CYP3A4 are expected to alter the concentrations of daclatasvir  (<a class="graphic graphic_table graphicRef109363" href="/d/graphic/109363.html" rel="external">table 1</a>). The typical dose is 60 mg once daily. An increase in the daclatasvir dose to 90 mg daily is indicated when used with <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a>, and a dose reduction to 30 mg daily is indicated when used with ritonavir- or cobicistat-boosted <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a>. Of note, boosted lopinavir or <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a> require no dose adjustment. Pending further data, we avoid use with <a class="drug drug_general" data-topicid="8902" href="/d/drug information/8902.html" rel="external">etravirine</a> because of the potential for lower daclatasvir levels.</p><p></p><p class="bulletIndent1">In a clinical trial of daclatasvir plus <a class="drug drug_general" data-topicid="91794" href="/d/drug information/91794.html" rel="external">sofosbuvir</a> in patients with coinfection, the following antiretroviral agents were allowed: <a class="drug drug_general" data-topicid="8842" href="/d/drug information/8842.html" rel="external">darunavir</a>, <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a>, and lopinavir (each ritonavir-boosted), <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a>, <a class="drug drug_general" data-topicid="9694" href="/d/drug information/9694.html" rel="external">nevirapine</a>, <a class="drug drug_general" data-topicid="16494" href="/d/drug information/16494.html" rel="external">rilpivirine</a>, <a class="drug drug_general" data-topicid="9451" href="/d/drug information/9451.html" rel="external">raltegravir</a>, <a class="drug drug_general" data-topicid="90345" href="/d/drug information/90345.html" rel="external">dolutegravir</a>, TDF, <a class="drug drug_general" data-topicid="8993" href="/d/drug information/8993.html" rel="external">abacavir</a>, <a class="drug drug_general" data-topicid="8594" href="/d/drug information/8594.html" rel="external">emtricitabine</a>, <a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">lamivudine</a>, <a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">zidovudine</a>, <a class="drug drug_general" data-topicid="9445" href="/d/drug information/9445.html" rel="external">maraviroc</a>, and <a class="drug drug_general" data-topicid="8609" href="/d/drug information/8609.html" rel="external">enfuvirtide</a> [<a href="#rid25">25</a>]. No clinically relevant drug interactions with bictegravir, <a class="drug drug_general" data-topicid="130319" href="/d/drug information/130319.html" rel="external">cabotegravir</a>, or <a class="drug drug_general" data-topicid="118920" href="/d/drug information/118920.html" rel="external">doravirine</a> are expected. </p><p></p><p class="bulletIndent1">Other important drug interactions with daclatasvir are discussed elsewhere and can be queried in the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate. (See  <a class="medical medical_review" href="/d/html/93242.html" rel="external">"Direct-acting antivirals for the treatment of hepatitis C virus infection", section on 'Daclatasvir'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">Ribavirin</a> — Important drug interactions between antiretroviral agents and ribavirin include direct interactions as well as combinations that potentiate adverse effects. </p><p></p><p class="bulletIndent1">Patients on atazanavir-containing ART may develop jaundice due to an increase in total serum bilirubin levels following initiation of <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a> [<a href="#rid50">50</a>]. The mechanism leading to this observation may be related to increased ribavirin-associated hemolysis in combination with decreased physiologic clearance of bilirubin due to <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a> use. Clinicians should discuss this potential side effect with patients who are taking atazanavir. Patients who develop jaundice should have assays for indirect hyperbilirubinemia to be certain that the total increase in serum bilirubin is consistent with the drug effect of atazanavir. An increase in direct bilirubin, which suggests hepatic disease rather than drug effect, would be of much greater concern.</p><p></p><p class="headingAnchor" id="H604836572"><span class="h1">PATIENT MONITORING</span><span class="headingEndMark"> — </span>Patients should be monitored for adherence and side effects, and, in some cases, viral load responses on therapy. This depends on the regimen used. As an example, for patients using <a class="drug drug_general" data-topicid="97562" href="/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a> while using a <a class="drug drug_general" data-topicid="9895" href="/d/drug information/9895.html" rel="external">tenofovir disoproxil fumarate</a> (TDF)-containing antiretroviral regimen, monitoring creatinine and urinalysis during HCV treatment to evaluate for renal toxicity is prudent. (See <a class="local">'Ledipasvir-sofosbuvir'</a> above.) </p><p class="headingAnchor" id="H870365768"><span class="h1">BARRIERS TO CARE</span><span class="headingEndMark"> — </span>Comorbidities and underlying psychiatric and substance abuse issues can complicate delivery of care for this complex patient population [<a href="#rid51">51-53</a>]. However, dedicated programs with case management and stabilization of psychiatric and addiction care can increase the success of treatment [<a href="#rid54">54</a>]. </p><p class="headingAnchor" id="H3080545905"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113060.html" rel="external">"Society guideline links: Hepatitis C virus infection"</a>.)</p><p class="headingAnchor" id="H59"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/4576.html" rel="external">"Patient education: Hepatitis C (Beyond the Basics)"</a>) </p><p></p><p class="headingAnchor" id="H60"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of therapy</strong> – The objective of hepatitis C virus (HCV) antiviral treatment is to cure the HCV infection, as reflected by a sustained virologic response, which is associated with substantial reductions in liver-related morbidity and mortality. Although patients with HIV/HCV coinfection traditionally had lower response rates to HCV treatment with peginterferon and <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a> compared with individuals without HIV, they appear to have comparable sustained virologic response rates with all oral, direct-acting antiviral (DAA) combination therapy. (See <a class="local">'Goals of therapy'</a> above and <a class="local">'Effect of HIV infection on response to HCV treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prioritization of patients with coinfection</strong> – With the availability of highly effective interferon-free, direct-acting antiviral combination regimens for HCV, a curative all-oral treatment is becoming a possibility for the vast-majority of patients, even those with HIV. Because of the more rapid progression to advanced liver disease in the setting of HIV infection, coinfection is one reason to prioritize a patient for HCV antiviral therapy. (See <a class="local">'Patient evaluation'</a> above and  <a class="medical medical_review" href="/d/html/15832.html" rel="external">"Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection", section on 'Deciding when to treat'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of ART and HCV antiviral initiation</strong> – In antiretroviral therapy (ART)-naïve patients with HIV/HCV coinfection, we generally initiate ART at least four to six weeks before starting HCV antiviral therapy. (See <a class="local">'Antiretroviral management'</a> above and <a class="local">'Potential drug interactions with ART'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Regimen selection</strong> <strong>and drug interactions</strong> – HCV antiviral regimen selection for patients with HIV/HCV coinfection is generally the same as for patients with HCV monoinfection, and most of the supporting evidence for these regimens is from studies in patients with monoinfection  (<a class="graphic graphic_algorithm graphicRef93587" href="/d/graphic/93587.html" rel="external">algorithm 1</a>). Where available, pangenotypic DAA combinations can facilitate therapy because they can be administered without genotype assessment. Regimen selection should take into account potential drug interactions between ART and HCV antiviral agents  (<a class="graphic graphic_table graphicRef109363" href="/d/graphic/109363.html" rel="external">table 1</a>). (See <a class="local">'HCV regimen selection'</a> above.) </p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kirk GD, Mehta SH, Astemborski J, et al. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med 2013; 158:658.</a></li><li><a class="nounderline abstract_t">Goedert JJ, Eyster ME, Lederman MM, et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002; 100:1584.</a></li><li><a class="nounderline abstract_t">Vogel M, Page E, Boesecke C, et al. Liver fibrosis progression after acute hepatitis C virus infection in HIV-positive individuals. Clin Infect Dis 2012; 54:556.</a></li><li><a class="nounderline abstract_t">Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632.</a></li><li><a class="nounderline abstract_t">Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 2014; 384:241.</a></li><li><a class="nounderline abstract_t">Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010; 51:1122.</a></li><li><a class="nounderline abstract_t">Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139:1593.</a></li><li><a class="nounderline abstract_t">Burgess SV, Hussaini T, Yoshida EM. Concordance of sustained virologic response at weeks 4, 12 and 24 post-treatment of hepatitis C in the era of new oral direct-acting antivirals: A concise review. Ann Hepatol 2016; 15:154.</a></li><li><a class="nounderline abstract_t">Chalouni M, Wittkop L, Bani-Sadr F, et al. Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfected participants. HIV Med 2021; 22:791.</a></li><li><a class="nounderline abstract_t">Corma-Gómez A, Macías J, Lacalle-Remigio JR, et al. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis. Clin Infect Dis 2021; 73:e2109.</a></li><li><a class="nounderline abstract_t">Chalouni M, Pol S, Sogni P, et al. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death. J Hepatol 2021; 74:37.</a></li><li><a class="nounderline abstract_t">Berenguer J, Alvarez-Pellicer J, Martín PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50:407.</a></li><li><a class="nounderline abstract_t">Merchante N, Rivero-Juárez A, Téllez F, et al. Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis. J Antimicrob Chemother 2018; 73:2435.</a></li><li><a class="nounderline abstract_t">Labarga P, Soriano V, Vispo ME, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007; 196:670.</a></li><li><a class="nounderline abstract_t">European Association for the Study of the Liver. Electronic address: <span class="__cf_email__" data-cfemail="7a1f1b0916151c1c13191f3a1f1b0916151c1c13191f541f0f">[email protected]</span>, Clinical Practice Guidelines Panel: Chair:, EASL Governing Board representative:, Panel members:. EASL recommendations on treatment of hepatitis C: Final update of the series☆. J Hepatol 2020; 73:1170.</a></li><li class="breakAll">Recommendations for Testing, Managing, and Treating Hepatitis C. Joint panel from the American Association of the Study of Liver Diseases and the Infectious Diseases Society of America. http://www.hcvguidelines.org/ (Accessed on July 01, 2023).</li><li class="breakAll">European AIDS Clinical Society Guidelines, version 11.0, October 2021. https://www.eacsociety.org/guidelines/eacs-guidelines/ (Accessed on January 25, 2022).</li><li class="breakAll">HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Joint panel from the American Association of the Study of Liver Diseases and the Infectious Diseases Society of America. http://www.hcvguidelines.org/ (Accessed on January 01, 2020).</li><li class="breakAll">Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (Accessed on March 01, 2020).</li><li><a class="nounderline abstract_t">Balagopal A, Kandathil AJ, Higgins YH, et al. Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfected patients. Hepatology 2014; 60:477.</a></li><li><a class="nounderline abstract_t">Bhattacharya D, Belperio PS, Shahoumian TA, et al. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice. Clin Infect Dis 2017; 64:1711.</a></li><li><a class="nounderline abstract_t">Berenguer J, Gil-Martin Á, Jarrin I, et al. All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings. Hepatology 2018; 68:32.</a></li><li><a class="nounderline abstract_t">Rockstroh JK, Lacombe K, Viani RM, et al. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. Clin Infect Dis 2018; 67:1010.</a></li><li><a class="nounderline abstract_t">Wyles D, Bräu N, Kottilil S, et al. Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study. Clin Infect Dis 2017; 65:6.</a></li><li><a class="nounderline abstract_t">Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med 2015; 373:714.</a></li><li><a class="nounderline abstract_t">Mandorfer M, Schwabl P, Steiner S, et al. Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease. AIDS 2016; 30:1039.</a></li><li><a class="nounderline abstract_t">Kurniawan J, Gani RA, Hasan I, et al. Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability. Indian J Gastroenterol 2018; 37:520.</a></li><li><a class="nounderline abstract_t">Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61:1127.</a></li><li><a class="nounderline abstract_t">Rockstroh JK, Ingiliz P, Petersen J, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease. Antivir Ther 2017; 22:225.</a></li><li><a class="nounderline abstract_t">Cordie A, Elsharkawy A, Abdel Alem S, et al. Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection. Trans R Soc Trop Med Hyg 2020; 114:232.</a></li><li><a class="nounderline abstract_t">Luetkemeyer AF, McDonald C, Ramgopal M, et al. 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens. Clin Infect Dis 2016; 62:1489.</a></li><li><a class="nounderline abstract_t">Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 2015; 313:1232.</a></li><li><a class="nounderline abstract_t">Naggie S, Cooper C, Saag M, et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med 2015; 373:705.</a></li><li><a class="nounderline abstract_t">Ingiliz P, Christensen S, Kimhofer T, et al. Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01). Clin Infect Dis 2016; 63:1320.</a></li><li><a class="nounderline abstract_t">Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015; 385:1087.</a></li><li><a class="nounderline abstract_t">Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2015; 2:e319.</a></li><li><a class="nounderline abstract_t">Braun DL, Hampel B, Kouyos R, et al. High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men. Clin Infect Dis 2019; 68:569.</a></li><li><a class="nounderline abstract_t">Mogalian E, Stamm LM, Osinusi A, et al. Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers. Clin Infect Dis 2018; 67:934.</a></li><li class="breakAll">Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) [package insert]. Foster City CA: Gilead Sciences; 2018.</li><li class="breakAll">Garrison K, Mogalian E, Zhang H, et al. Evaluation of drug-drug interactions between sofosbuvir/velpatasvir/voxilaprevir and boosted or unboosted HIV antiretroviral regimens. Presented at the 18th International Workshop on Clinical Pharmacology of Antiviral Therapy, Chicago Il: June 14-17 2017.</li><li><a class="nounderline abstract_t">Dumond JB, Vourvahis M, Rezk NL, et al. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther 2010; 87:735.</a></li><li class="breakAll">Biktarvy European product information. https://www.ema.europa.eu/documents/product-information/biktarvy-epar-product-information_en.pdf (Accessed on January 09, 2019).</li><li class="breakAll">Harvoni (ledipasvir-sofosbuvir). US FDA approved product information. National Library of Medicine.</li><li class="breakAll">German P, Pang PS, Fang L, et al. Drug-drug interaction profile of the fixed-dose combination tablet ledipasvir/sofosbuvir. Presented at the American Association for the Study of Liver Diseases Liver Meeting, Boston MA, November 7-11, 2014. Abstract #1976.</li><li class="breakAll">MacBrayne C, Fierer DS, Marks KM, et al. Ledipasvir/sofosbuvir raises tenofovir diphosphate concentrations in red cells. Presented at the Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 13-16, 2017, Abstract #404.</li><li class="breakAll">Garrison K, Custodio J, Pang P, et al. Drug interactions between anti-HCV antivirals ledipasvir/sofosbuvir and integrase strand transfer inhibitor-based regimens. Presented at the 16th International Workshop on Clinical Pharmacology of HIV. Washington, DC. May 26, 2015, Abstract #71.</li><li class="breakAll">Custodio J, et al. Tenofovir (TFV) exposures: Coadministration of LDV/SOF with E/C/F/TAF or R/F/TAF vs other ARVs. Presented at IDWeek, San Diego, CA, October 7 - 11, 2015. Abstract #727.</li><li><a class="nounderline abstract_t">Wilby KJ, Eissa NA. Clinical Pharmacokinetics and Drug Interactions of Doravirine. Eur J Drug Metab Pharmacokinet 2018; 43:637.</a></li><li><a class="nounderline abstract_t">Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014; 312:353.</a></li><li><a class="nounderline abstract_t">Rodríguez-Nóvoa S, Morello J, González M, et al. Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. AIDS 2008; 22:2535.</a></li><li><a class="nounderline abstract_t">Fleming CA, Craven DE, Thornton D, et al. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36:97.</a></li><li><a class="nounderline abstract_t">Mehta SH, Lucas GM, Mirel LB, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 2006; 20:2361.</a></li><li><a class="nounderline abstract_t">Butt AA, Khan UA, Shaikh OS, et al. Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers. HIV Clin Trials 2009; 10:25.</a></li><li><a class="nounderline abstract_t">Taylor LE, Schwartzapfel B, Allen S, et al. Extending treatment for HCV infection to HIV-HCV coinfected individuals with psychiatric illness and drug dependence. Clin Infect Dis 2003; 36:1501.</a></li></ol></div><div id="topicVersionRevision">Topic 3701 Version 71.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23440167" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12176875" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : End-stage liver disease in persons with hemophilia and transfusion-associated infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22156856" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Liver fibrosis progression after acute hepatitis C virus infection in HIV-positive individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16908797" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25042234" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20069649" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20637202" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31196396" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Concordance of sustained virologic response at weeks 4, 12 and 24 post-treatment of hepatitis C in the era of new oral direct-acting antivirals: A concise review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34212476" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfected participants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32766891" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32798585" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19575364" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29982683" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17674307" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32956768" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : EASL recommendations on treatment of hepatitis C: Final update of the series☆.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32956768" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : EASL recommendations on treatment of hepatitis C: Final update of the series☆.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32956768" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : EASL recommendations on treatment of hepatitis C: Final update of the series☆.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32956768" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : EASL recommendations on treatment of hepatitis C: Final update of the series☆.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32956768" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : EASL recommendations on treatment of hepatitis C: Final update of the series☆.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24706559" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28199525" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29377274" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29566246" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28369210" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26196502" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26760453" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30637537" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25614962" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27845298" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31925434" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27025835" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25706232" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26196665" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27535952" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25467560" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26423374" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30107485" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29522076" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29522076" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29522076" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20147896" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20147896" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20147896" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20147896" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20147896" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20147896" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20147896" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30047107" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical Pharmacokinetics and Drug Interactions of Doravirine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25038354" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19005277" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12491208" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17117023" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19362993" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12766851" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Extending treatment for HCV infection to HIV-HCV coinfected individuals with psychiatric illness and drug dependence.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
